Acceptability of blood‐based biomarkers for liver cancer surveillance: consumer and clinician perspectives

View at publisher Summarise with VIRAT
Authors: Lucinda Vaux, Angela E. Carberry, Rhian Jones, Mikaela Daniells, Brooke Gaggin, Lewis Smith, James P. O’Beirne
Cited by: 0
References: 19

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

This survey assessed consumer and clinician perspectives on hepatocellular carcinoma surveillance and the role of blood-based biomarkers. Consumers reported comfort with both ultrasound and blood tests, with a preference for combined surveillance. Clinicians strongly supported biomarkers but were hesitant to remove ultrasound from surveillance. Both groups demonstrated high confidence in future surveillance participation. However, findings are limited by a relatively small sample size and recruitment of consumers from a single health service and clinicians predominantly from metropolitan centres. Overall, the results demonstrate confidence in current surveillance and support for blood-based biomarkers. The successful integration of biomarkers requires targeted education to address current consumer and clinicians' perspectives.

Fields of Study & Subjects

Hepatocellular Carcinoma Treatment and Prognosis Patient-Provider Communication in Healthcare Liver Disease Diagnosis and Treatment

Publication details

Journal / source
Internal Medicine Journal
Volume
56
Issue
5
Pages
893–896
Publication date
25 March 2026
Language
EN